A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia - Müller-Tidow, Carsten; Bug, Gesine; Lübbert, Michael; Krämer, Alwin; Krauter, Jürgen; Valent, Peter; Nachbaur, David; Berdel, Wolfgang E.; Ottmann, Oliver G.; Fritsch, Holger; Munzert, Gerd; Garin-Chesa, Pilar; et al. (British journal of haematology, 2013)